Neurocrine Biosciences, Inc.
NBIX
$131.14
-$1.24-0.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.86B | 2.68B | 2.51B | 2.41B | 2.36B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.86B | 2.68B | 2.51B | 2.41B | 2.36B |
| Cost of Revenue | 1.07B | 986.90M | 925.90M | 870.60M | 765.10M |
| Gross Profit | 1.79B | 1.70B | 1.58B | 1.54B | 1.59B |
| SG&A Expenses | 1.16B | 1.14B | 1.08B | 1.03B | 993.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.22B | 2.13B | 2.01B | 1.90B | 1.76B |
| Operating Income | 635.80M | 553.60M | 499.10M | 515.40M | 597.00M |
| Income Before Tax | 705.40M | 628.60M | 527.10M | 466.20M | 486.00M |
| Income Tax Expenses | 226.80M | 200.60M | 178.80M | 160.40M | 144.70M |
| Earnings from Continuing Operations | 478.60 | 428.00 | 348.30 | 305.80 | 341.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 478.60M | 428.00M | 348.30M | 305.80M | 341.30M |
| EBIT | 635.80M | 553.60M | 499.10M | 515.40M | 597.00M |
| EBITDA | 665.90M | 583.30M | 527.60M | 543.90M | 624.10M |
| EPS Basic | 4.81 | 4.30 | 3.48 | 3.04 | 3.39 |
| Normalized Basic EPS | 4.56 | 4.02 | 3.67 | 3.76 | 4.28 |
| EPS Diluted | 4.66 | 4.18 | 3.38 | 2.95 | 3.29 |
| Normalized Diluted EPS | 4.42 | 3.92 | 3.57 | 3.65 | 4.15 |
| Average Basic Shares Outstanding | 398.00M | 398.10M | 399.80M | 401.60M | 401.70M |
| Average Diluted Shares Outstanding | 409.70M | 408.90M | 410.70M | 413.60M | 414.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |